Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)
Clinical trial NCT05255406 · UNKNOWN
Trial details
- NCT number
- NCT05255406
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-09
- Primary completion
- 2023-12-31
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.